ArticleJAMA2023
Medicare Advantage Enrollment Among Beneficiaries With End-Stage Renal Disease in the First Year of the 21st Century Cures Act.
Article in JAMA, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 21 citations in OpenAlex.
- End-Stage Renal Disease Treatment Choices Model and Use of Home Dialysis and Kidney Transplant.JAMA health forum · 2026Article
- Medicare Advantage Enrollment in Nursing Homes: 2010-2023.Journal of the American Geriatrics Society · 2026Article
- What is Medicare Advantage and Why is it the Most Important Contemporary Policy Affecting Kidney Disease?American journal of kidney diseases : the official journal of the National Kidney Foundation · 2026Review
- Medicare Advantage Enrollment Increased Disproportionately In Chain-Owned Dialysis Facilities After The Cures Act.Health affairs (Project Hope) · 2025Article
- Medicare Advantage Plan and Chronic Kidney Disease Care Management Company Partnerships After the 21st Century Cures Act.Medical care research and review : MCRR · 2025Article
- Expansion and Marketing of Medicare Advantage to Persons With End-Stage Kidney Disease.JAMA network open · 2025Article
- Implications of Increased Medicare Advantage Enrollment for Access to Kidney Transplant Waitlisting.Journal of the American Society of Nephrology : JASN · 2025Article
- Evaluating access to care for Medicare beneficiaries younger than 65 Years.The American journal of managed care · 2025Article
- Care Continuity, Nephrologists' Dialysis Facility Preferences, and Outcomes.JAMA health forum · 2025Article
- Racial and Ethnic Differences in Potentially Inappropriate Medication Use Among Medicare Beneficiaries.JAMA network open · 2025Article
- Should I stay or should I go again: Multiple switching between fee-for-service Medicare and Medicare advantage among older beneficiaries.Health services research · 2025Article
- Dialysis Facility Participation In Medicare Advantage Networks Was Highest For Large Dialysis Organizations In 2021.Health affairs (Project Hope) · 2025Article
- Medicare Enrollment and Spending Among Patients Initiating Dialysis After the Affordable Care Act.JAMA health forum · 2024Article
- Impact of Medicaid expansion on kidney transplantation in the State Oklahoma.World journal of transplantation · 2024Article
- Medicare Advantage Enrollment Following the 21st Century Cures Act in Adults With End-Stage Renal Disease.JAMA network open · 2024Article
- Comparing Medicare Fee-for-Service Beneficiaries with ESKD Who Switched to Medicare Advantage versus Remained in Traditional Medicare.Clinical journal of the American Society of Nephrology : CJASN · 2024Article
- Total and Out-of-Pocket Costs Surrounding Emergency Department Care Among Older Adults Enrolled in Traditional Medicare and Medicare Advantage.Annals of emergency medicine · 2024Article
- Pay-for-Performance Incentives for Home Dialysis Use and Kidney Transplant.JAMA health forum · 2024Article
- Prescription and Dispensation of QT-Prolonging Medications in Individuals Receiving Hemodialysis.JAMA network open · 2024Article
- Social Risk and Dialysis Facility Performance in the First Year of the ESRD Treatment Choices Model.JAMA · 2024Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Importance: Before 2021, most Medicare beneficiaries with end-stage renal disease (ESRD) were unable to enroll in private Medicare Advantage (MA) plans. The 21st Century Cures Act permitted these beneficiaries to enroll in MA plans effective January 2021. Objective: To examine changes in MA enrollment among Medicare beneficiaries with ESRD after enactment of the 21st Century Cures Act overall and by race or ethnicity and dual-eligible status. Design, Setting, and Participants: This cross-sectional time-trend study used data from Medicare beneficiaries with ESRD (both kidney transplant recipients and those undergoing dialysis) between January 2019 and December 2021. Data were analyzed between June and October 2022. Exposures: 21st Century Cures Act. Main Outcomes and Measures: Primary outcomes were the proportion of Medicare beneficiaries with prevalent ESRD who switched from traditional Medicare to MA between 2020 and 2021 and those with incident ESRD who newly enrolled in MA in 2021. Individuals who stayed in traditional Medicare were enrolled in 2020 and 2021 and those who switched to MA were enrolled in traditional Medicare in 2020 and MA in 2021. Results: Among 575 797 beneficiaries with ESRD in 2020 or 2021 (mean [SD] age, 64.7 [14.2] years, 42.2% female, 34.0% Black, and 7.7% Hispanic or Latino), the proportion of beneficiaries enrolled in MA increased from 24.8% (December 2020) to 37.4% (December 2021), a relative change of 50.8%. The largest relative increases in MA enrollment were among Black (72.8% relative increase), Hispanic (44.8%), and dual-eligible beneficiaries with ESRD (73.6%). Among 359 617 beneficiaries with TM and prevalent ESRD in 2020, 17.6% switched to MA in 2021. Compared with individuals who stayed in traditional Medicare, those who switched to MA had modestly more chronic conditions (6.3 vs 6.1; difference, 0.12 conditions [95% CI, 0.10-0.16]) and similar nondrug spending in 2020 (difference, $509 [95% CI, -$58 to $1075]) but were more likely to be Black (difference, 19.5 percentage points [95% CI, 19.1-19.9]) and have dual Medicare-Medicaid eligibility (difference, 20.8 percentage points [95% CI, 20.4-21.2]). Among beneficiaries who were newly eligible for Medicare ESRD benefits in 2021, 35.2% enrolled in MA. Conclusions and Relevance: Results suggest that increases in MA enrollment among Medicare beneficiaries with ESRD were substantial the first year after the 21st Century Cures Act, particularly among Black, Hispanic, and dual-eligible individuals. Policy makers and MA plans may need to assess network adequacy, disenrollment, and equity of care for beneficiaries who enrolled in MA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.